CHMP backs Merck’s Ebola vaccine, a first

EMA’s CHMP issued its first positive opinion for an Ebola vaccine and backed AbbVie’s rheumatoid arthritis treatment.

The agency recommended approving Ervebo (rVSV-ZEBOV) from Merck & Co. Inc. (NYSE:MRK), to prevent infection by

Read the full 322 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE